JP6556156B2 - Ａｐｒｉｌバリアント - Google Patents

Ａｐｒｉｌバリアント Download PDF

Info

Publication number
JP6556156B2
JP6556156B2 JP2016553489A JP2016553489A JP6556156B2 JP 6556156 B2 JP6556156 B2 JP 6556156B2 JP 2016553489 A JP2016553489 A JP 2016553489A JP 2016553489 A JP2016553489 A JP 2016553489A JP 6556156 B2 JP6556156 B2 JP 6556156B2
Authority
JP
Japan
Prior art keywords
april
cell
bcma
cells
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016553489A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514787A (ja
JP2017514787A5 (enExample
Inventor
マーティン プーレ，
マーティン プーレ，
クエ ヨン，
クエ ヨン，
リディア リー，
リディア リー，
ニール チャプリン，
ニール チャプリン，
ベン ドレイパー，
ベン ドレイパー，
Original Assignee
ユーシーエル ビジネス ピーエルシー
ユーシーエル ビジネス ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403479A external-priority patent/GB201403479D0/en
Priority claimed from GB201403481A external-priority patent/GB201403481D0/en
Priority claimed from GB201409759A external-priority patent/GB201409759D0/en
Priority claimed from GB201409761A external-priority patent/GB201409761D0/en
Application filed by ユーシーエル ビジネス ピーエルシー, ユーシーエル ビジネス ピーエルシー filed Critical ユーシーエル ビジネス ピーエルシー
Publication of JP2017514787A publication Critical patent/JP2017514787A/ja
Publication of JP2017514787A5 publication Critical patent/JP2017514787A5/ja
Application granted granted Critical
Publication of JP6556156B2 publication Critical patent/JP6556156B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
JP2016553489A 2014-02-27 2015-02-26 Ａｐｒｉｌバリアント Expired - Fee Related JP6556156B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403479A GB201403479D0 (en) 2014-02-27 2014-02-27 Molecule
GB1403479.7 2014-02-27
GB201403481A GB201403481D0 (en) 2014-02-27 2014-02-27 Chimeric antigen receptor
GB1403481.3 2014-02-27
GB1409759.6 2014-06-02
GB201409759A GB201409759D0 (en) 2014-06-02 2014-06-02 Molecule
GB201409761A GB201409761D0 (en) 2014-06-02 2014-06-02 Chimeric antigen receptor
GB1409761.2 2014-06-02
PCT/GB2015/050557 WO2015128653A2 (en) 2014-02-27 2015-02-26 Ligand

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017107701A Division JP6707496B2 (ja) 2014-02-27 2017-05-31 Ａｐｒｉｌバリアント
JP2019014039A Division JP2019068855A (ja) 2014-02-27 2019-01-30 Ａｐｒｉｌバリアント

Publications (3)

Publication Number Publication Date
JP2017514787A JP2017514787A (ja) 2017-06-08
JP2017514787A5 JP2017514787A5 (enExample) 2018-02-15
JP6556156B2 true JP6556156B2 (ja) 2019-08-07

Family

ID=52633311

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016553489A Expired - Fee Related JP6556156B2 (ja) 2014-02-27 2015-02-26 Ａｐｒｉｌバリアント
JP2017107701A Expired - Fee Related JP6707496B2 (ja) 2014-02-27 2017-05-31 Ａｐｒｉｌバリアント
JP2019014039A Pending JP2019068855A (ja) 2014-02-27 2019-01-30 Ａｐｒｉｌバリアント

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017107701A Expired - Fee Related JP6707496B2 (ja) 2014-02-27 2017-05-31 Ａｐｒｉｌバリアント
JP2019014039A Pending JP2019068855A (ja) 2014-02-27 2019-01-30 Ａｐｒｉｌバリアント

Country Status (8)

Country Link
US (2) US10752665B2 (enExample)
EP (2) EP3243831A1 (enExample)
JP (3) JP6556156B2 (enExample)
CN (1) CN106414502A (enExample)
AU (1) AU2015221933B2 (enExample)
CA (1) CA2939411A1 (enExample)
ES (1) ES2737690T3 (enExample)
WO (1) WO2015128653A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015128653A2 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
JP6921001B2 (ja) 2015-04-13 2021-08-18 ファイザー・インク Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
SG10202012157QA (en) 2016-06-07 2021-01-28 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
WO2018121679A1 (zh) * 2016-12-30 2018-07-05 四川大学 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
AU2018226857B2 (en) 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
KR20250010043A (ko) * 2017-10-18 2025-01-20 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
KR20200079511A (ko) 2017-11-01 2020-07-03 허밍버드 바이오사이언스 홀딩스 피티이. 엘티디. Cd47 항원-결합 분자
GB201720426D0 (en) * 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
US20210054086A1 (en) * 2018-01-10 2021-02-25 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
US20200054675A1 (en) 2018-06-01 2020-02-20 Washington University Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy
CA3103610A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
WO2020247618A1 (en) * 2019-06-04 2020-12-10 The General Hospital Corporation Antibodies and chimeric antigen receptors that target taci
CN110642953B (zh) * 2019-10-12 2021-09-17 华夏源（上海）细胞基因工程股份有限公司 一种靶向bcma的t细胞受体融合蛋白和应用
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2024097311A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Hypoimmunogenic mail cells, methods of making and methods of using same
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025209465A1 (zh) * 2024-04-02 2025-10-09 福佑泰生物制药公司 Taci/bcma嵌合体融合蛋白及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JP5062606B2 (ja) 2000-02-16 2012-10-31 ジェネンテック， インコーポレイテッド Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
AU2003268230A1 (en) 2002-08-30 2004-03-19 Incyte Corporation Immune response associated proteins
WO2004089982A2 (en) 2003-01-06 2004-10-21 Xencor April variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050003480A1 (en) * 2003-01-06 2005-01-06 Xencor April variants and methods thereof
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
WO2015128653A2 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
CN110114371A (zh) 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体

Also Published As

Publication number Publication date
AU2015221933A1 (en) 2016-09-01
JP2017514787A (ja) 2017-06-08
CA2939411A1 (en) 2015-09-03
US20160362467A1 (en) 2016-12-15
EP3110838B1 (en) 2019-06-26
EP3243831A1 (en) 2017-11-15
WO2015128653A2 (en) 2015-09-03
US20170334964A1 (en) 2017-11-23
AU2015221933B2 (en) 2019-09-12
ES2737690T3 (es) 2020-01-15
US10752665B2 (en) 2020-08-25
JP2019068855A (ja) 2019-05-09
JP6707496B2 (ja) 2020-06-10
US10611811B2 (en) 2020-04-07
WO2015128653A3 (en) 2015-11-05
JP2017145258A (ja) 2017-08-24
CN106414502A (zh) 2017-02-15
EP3110838A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
JP6556156B2 (ja) Ａｐｒｉｌバリアント
US20260062458A1 (en) Chimeric antigen receptor
JP7149304B2 (ja) Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ）
JP6557657B2 (ja) 分子
WO2022093694A1 (en) Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof
HK1227893B (en) April variants
HK1227893A1 (en) April variants
WO2024119819A1 (zh) 一种多肽标签及其应用
WO2020241827A1 (ja) Ａｌｋを標的とするキメラ抗原受容体発現細胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190709

R150 Certificate of patent or registration of utility model

Ref document number: 6556156

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees